South Korean biotech company Matika Bio and U.S. firm VaxDome have joined forces to develop a hybrid antiviral vaccine that can combat various virus strains. This collaboration signals a significant advancement in Korea's biotech sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned